307 related articles for article (PubMed ID: 29764407)
1. Are we doing enough to prevent poor-quality antimalarial medicines in the developing world?
Walker EJ; Peterson GM; Grech J; Paragalli E; Thomas J
BMC Public Health; 2018 May; 18(1):630. PubMed ID: 29764407
[TBL] [Abstract][Full Text] [Related]
2. Poor-quality antimalarials further health inequities in Uganda.
Evans DR; Higgins CR; Laing SK; Awor P; Ozawa S
Health Policy Plan; 2019 Dec; 34(Supplement_3):iii36-iii47. PubMed ID: 31816072
[TBL] [Abstract][Full Text] [Related]
3. Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model.
Jackson KD; Higgins CR; Laing SK; Mwila C; Kobayashi T; Ippolito MM; Sylvia S; Ozawa S
BMC Public Health; 2020 Jul; 20(1):1083. PubMed ID: 32646393
[TBL] [Abstract][Full Text] [Related]
4. Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa.
Renschler JP; Walters KM; Newton PN; Laxminarayan R
Am J Trop Med Hyg; 2015 Jun; 92(6 Suppl):119-126. PubMed ID: 25897068
[TBL] [Abstract][Full Text] [Related]
5. Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo.
Ozawa S; Haynie DG; Bessias S; Laing SK; Ngamasana EL; Yemeke TT; Evans DR
Am J Trop Med Hyg; 2019 May; 100(5):1149-1157. PubMed ID: 30675851
[TBL] [Abstract][Full Text] [Related]
6. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study.
Ozawa S; Evans DR; Higgins CR; Laing SK; Awor P
Malar J; 2019 Jan; 18(1):5. PubMed ID: 30626380
[TBL] [Abstract][Full Text] [Related]
7. Global scenario of counterfeit antimalarials: A potential threat.
Arora T; Sharma S
J Vector Borne Dis; 2019; 56(4):288-294. PubMed ID: 33269727
[TBL] [Abstract][Full Text] [Related]
8. Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy.
Nsimba SE
East Afr J Public Health; 2008 Dec; 5(3):205-10. PubMed ID: 19374325
[TBL] [Abstract][Full Text] [Related]
9. Combating poor-quality anti-malarial medicines: a call to action.
Bassat Q; Tanner M; Guerin PJ; Stricker K; Hamed K
Malar J; 2016 Jun; 15():302. PubMed ID: 27251199
[TBL] [Abstract][Full Text] [Related]
10. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
Petersen A; Held N; Heide L;
PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
[TBL] [Abstract][Full Text] [Related]
11. The economic impact of substandard and falsified antimalarial medications in Nigeria.
Beargie SM; Higgins CR; Evans DR; Laing SK; Erim D; Ozawa S
PLoS One; 2019; 14(8):e0217910. PubMed ID: 31415560
[TBL] [Abstract][Full Text] [Related]
12. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
13. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
[TBL] [Abstract][Full Text] [Related]
14. An empirical review of antimalarial quality field surveys: the importance of characterising outcomes.
Grech J; Robertson J; Thomas J; Cooper G; Naunton M; Kelly T
J Pharm Biomed Anal; 2018 Jan; 147():612-623. PubMed ID: 28549854
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
[TBL] [Abstract][Full Text] [Related]
17. The role of antimalarial quality in the emergence and transmission of resistance.
Brock AR; Ross JV; Parikh S; Esterman A
Med Hypotheses; 2018 Feb; 111():49-54. PubMed ID: 29406996
[TBL] [Abstract][Full Text] [Related]
18. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa.
Nayyar GM; Breman JG; Newton PN; Herrington J
Lancet Infect Dis; 2012 Jun; 12(6):488-96. PubMed ID: 22632187
[TBL] [Abstract][Full Text] [Related]
19. Health, Economic, and Social Impacts of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review of Methodological Approaches.
Salami RK; Valente de Almeida S; Gheorghe A; Njenga S; Silva W; Hauck K
Am J Trop Med Hyg; 2023 Aug; 109(2):228-240. PubMed ID: 37339762
[TBL] [Abstract][Full Text] [Related]
20. Detection of Poor Quality Artemisinin-based Combination Therapy (ACT) Medicines Marketed in Benin Using Simple and Advanced Analytical Techniques.
Yemoa A; Habyalimana V; Mbinze JK; Crickboom V; Muhigirwa B; Ngoya A; Sacre PY; Gbaguidi F; Quetin-Leclercq J; Hubert P; Marini RD
Curr Drug Saf; 2017; 12(3):178-186. PubMed ID: 28625144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
